The hazards of interrupting anticoagulation therapy in atrial fibrillation

European Heart Journal

Volumn 33, Issue 15, 2012, Pages 1864-1866

  Hohnloser, Stefan H ^a   Eikelboom, John W ^b  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN; RIVAROXABAN; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; CARDIOVASCULAR RISK; CLINICAL PRACTICE; COMPETITIVE INHIBITION; DEATH; DEFIBRILLATOR; DISEASE ASSOCIATION; EDITORIAL; FOLLOW UP; HEART ATRIUM FIBRILLATION; HOSPITAL DISCHARGE; HUMAN; INTERNATIONAL NORMALIZED RATIO; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RECURRENT DISEASE; RISK ASSESSMENT; SCORING SYSTEM; STROKE; THROMBOEMBOLISM;

ANTICOAGULANTS; ATRIAL FIBRILLATION; FEMALE; HUMANS; MALE; THROMBOEMBOLISM; WARFARIN; WITHHOLDING TREATMENT;

EID: 84864581976     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehs032     Document Type: Editorial

References (16)

1. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146:857-867.
2. Eikelboom JW, Weitz JI. Update on antithrombotic therapy. New anticoagulants. Circulation 2010;121:1523-1532
3. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007;115:2689-2696.
4. Glader EL, Sjölander M, Eriksson M, Lundberg M. Persistent use of secondary preventive drugs declines rapidly during the first 2 years after stroke. Stroke 2010;41: 397-401.
5. Raunsø J, Selmer C, Olesen JB, Charlot MG, Olsen A-MS, Bretler D-M, Nielsen JD, Dominguez H, Gadsbøll N, Køber L, Gislason GH, Torp- Pedersen C, Hansen ML. Increased short-term risk of thrombo-embolism or death after interruption of warfarin treatment in patients with atrial fibrillation. Eur Heart J 2012;33:1886-1892.
6. Palareti G, Legnani C, Guazzaloca G, Frascaro M, Grauso F, De Rosa F, Fortunato G, Coccheri S. Activation of blood coagulation after abrupt or stepwise withdrawal of oral anticoagulants-a prospective study. Thromb Haemost 1994;72: 222-226.
7. Ascani A, Iorio A, Agnelli G. Withdrawal of warfarin after deep vein thrombosis: effects of a low fixed dose on rebound thrombin generation. Blood Coagul Fibrinolysis 1999;10:291-295.
8. Boutitie F, Pinede L, Schulman S, Agnelli G, Raskob G, Julian J, Kearon C. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials. BMJ 2011;342:d3036.
9. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-891.
10. Garcia Ridriguez LA, Cea-Soriano L, Martin-Merino E, Johansson S. Discontinuation of low dose aspirin and risk of myocardial infarction: case-control study in UK primary care. BMJ 2011;343:pd4094.
11. Ho PM, Peterson ED, Wang L, Magid DJ, Fihn SD, Larsen GC, Jesse RA, Runsfeld JS. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA 2008;299:532-539.
12. Bijsterveld NR, Moons AH, Meijers JC, Tijssen JG, Büller HR, Levi M, Peters RJ. Rebound thrombin generation after heparin therapy in unstable angina. A randomized comparison between unfractionated and low-molecular-weight heparin. J Am Coll Cardiol 2002;39:811-817.
13. Tompkins C, Cheng A, Dalal D, Brinker JA, Leng CT, Marine JE, Nazarian S, Spragg DD, Sinha S, Halperin H, Tomaselli GF, Berger RD, Calkins H, Henrikson CA. Dual antiplatelet, heparin therapy 'bridging' significantly increase the risk of bleeding complications after pacemaker or implantable cardioverterdefibrillator device implantation. J Am Coll Cardiol 2010;55:2376-2382.
14. Tolosana JM, Berne P, Mont L, Heras M, Berruezo A, Monteagudo J, Tamborrero D, Benito B, Brugada J. Preparation for pacemaker or implantable cardiac defibrillator implants in patients with high risk of thrombo-ebolic events: oral anticoagulation or bridging with intravenous heparin? A prospective randomized comparison. Eur Heart J 2009;30:1880-1884.
15. Ahmed I, Gertner E, Nelson BW, House CM, Dahiya R, Anderson CP, Benditt DG. Continuing warfarin therapy is superior to interrupting warfarin with or without bridging anticoagulation therapy in patients undergoing pacemaker and defibrillator implantation. Heart Rhythm 2010;7:745-749.
16. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH, Vahanian A, Auricchio A, Bax J, Ceconi C, Dean V, Filippatos G, Funck-Brentano C, Hobbs R, Kearney P, McDonagh T, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Vardas PE, Widimsky P, Agladze V, Aliot E, Balabanski T, Blomstrom-Lundqvist C, Capucci A, Crijns H, Dahlof B, Folliguet T, Glikson M, Goethals M, Gulba DC, Ho SY, Klautz RJM, Kose S, McMurray J, Perrone Filardi P, Raatikainen P, Salvador MJ, Schalij MJ, Shpektor A, Sousa J, Stepinska J, Uuetoa H, Zamorano JL, Zupan I. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369-2429.